194
Participants
Start Date
November 12, 2020
Primary Completion Date
April 25, 2022
Study Completion Date
September 13, 2022
Benralizumab
Benralizumab by subcutaneous injection until Week 16, and then benralizumab by subcutaneous injection during the extension period.
Placebo / Benralizumab
Placebo by subcutaneous injection until Week 16, then benralizumab by subcutaneous injection until Week 52.
Research Site, Sofia
Research Site, Sofia
Research Site, Kogarah
Research Site, Parkville
Research Site, Sippy Downs
Research Site, Seoul
Research Site, Pleven
Research Site, Haskovo
Research Site, New York
Research Site, Seongnam-si
Research Site, Córdoba
Research Site, Rochester
Research Site, Ansan-si
Research Site, Sugarloaf
Research Site, Madrid
Research Site, Brest
Research Site, Tampa
Research Site, Tampa
Research Site, Fort Myers
Research Site, Daegu
Research Site, Cincinnati
Research Site, Manises
Research Site, Ypsilanti
Research Site, Yangsan
Research Site, Lille
Research Site, Gwangju
Research Site, Norman
Research Site, Osielsko
Research Site, Los Angeles
Research Site, Newport Beach
Research Site, Bridgeport
Research Site, Portsmouth
Research Site, Woolloongabba
Research Site, Brno
Research Site, Ostrava
Research Site, Ostrava-Poruba
Research Site, Pardubice
Research Site, Prague
Research Site, Prague
Research Site, Krakow
Research Site, Lodz
Research Site, Poznan
Research Site, Warsaw
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Alicante
Research Site, Barcelona
Lead Sponsor
Iqvia Pty Ltd
INDUSTRY
AstraZeneca
INDUSTRY